Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Sandblom, Viktor"'
Autor:
Sandblom, Viktor, Ståhl, Ingun, Hansson, Christoffer, Olofsson Bagge, Roger, Forssell-Aronsson, Eva
Publikováno v:
In Surgical Oncology June 2019 29:148-156
Autor:
Sandblom, Viktor1 (AUTHOR) viktor.sandblom@vgregion.se, Spetz, Johan1 (AUTHOR), Shubbar, Emman1 (AUTHOR), Montelius, Mikael1 (AUTHOR), Ståhl, Ingun1,2 (AUTHOR), Swanpalmer, John1,2 (AUTHOR), Nilsson, Ola3 (AUTHOR), Forssell-Aronsson, Eva1,2 (AUTHOR)
Publikováno v:
PLoS ONE. 5/27/2020, Vol. 15 Issue 5, p1-14. 14p.
Autor:
Sandblom, Viktor1 (AUTHOR) viktor.sandblom@gu.se, Spetz, Johan1 (AUTHOR), Shubbar, Emman1 (AUTHOR), Montelius, Mikael1 (AUTHOR), Ståhl, Ingun1,2 (AUTHOR), Swanpalmer, John1,2 (AUTHOR), Nilsson, Ola3 (AUTHOR), Forssell-Aronsson, Eva1,2 (AUTHOR)
Publikováno v:
PLoS ONE. 11/14/2019, Vol. 14 Issue 11, p1-17. 17p.
Autor:
Hofving, Tobias, Sandblom, Viktor, Arvidsson, Yvonne, Shubbar, Emman, Altiparmak, Gülay, Swanpalmer, John, Almobarak, Bilal, Elf, Anna-Karin, Johanson, Viktor, Elias, Erik, Kristiansson, Erik, Forssell-Aronsson, Eva, Nilsson, Ola
Publikováno v:
Endocrine-Related Cancer
177Lu-octreotate is an FDA-approved radionuclide therapy for patients with gastroenteropancreatic neuroendocrine tumours (NETs) expressing somatostatin receptors. The 177Lu-octreotate therapy has shown promising results in clinical trials by prolongi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::54424c8a42e4ef7552b7fd70553615fd
http://europepmc.org/articles/PMC6391910
http://europepmc.org/articles/PMC6391910
Autor:
Sandblom, Viktor1 viktor.sandblom@gu.se, Ståhl, Ingun1 ingun.stahl@gu.se, Olofsson Bagge, Roger2 roger.olofsson@gu.se, Forssell-Aronsson, Eva1 eva.forssell_aronsson@radfys.gu.se
Publikováno v:
EJNMMI Physics. 1/9/2017, Vol. 4 Issue 1, p1-15. 15p.
Autor:
Sandblom, Viktor
Neuroendocrine tumours (NETs) are a group of heterogeneous tumour types that originate in hormone-producing organs. Patients with NETs are often diagnosed after the primary tumour has metastasised. One treatment option for these patients that has sho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______1149::313a5e2d53f4f016db4677a24309313c
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
EJNMMI Physics
Background Patients with somatostatin receptor-expressing neuroendocrine tumours can be treated with intravenously administered 177Lu-octreotate. Few patients are cured with the present protocol due to the current dose limitation of normal organs at
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::9795b3ca650bfd4b723e1c9da166098f
http://europepmc.org/articles/PMC5222763
http://europepmc.org/articles/PMC5222763
Autor:
Hofving, Tobias, Sandblom, Viktor, Arvidsson, Yvonne, Shubbar, Emman, Altiparmak, Gülay, Swanpalmer, John, Almobarak, Bilal, Elf, Anna-Karin, Johanson, Viktor, Elias, Erik, Kristiansson, Erik, Forssell-Aronsson, Eva, Nilsson, Ola
Publikováno v:
Endocrine-Related Cancer; Apr2019, Vol. 26 Issue 4, p437-449, 13p
Autor:
Sandblom, Viktor, Spetz, Johan, Shubbar, Emman, Ståhl, Ingun, Swanpalmer, John, Forssell-Aronsson, Eva
Publikováno v:
In Physica Medica August 2018 52 Supplement 1:62-63